Judith López

Endocrinología y Nutrición. Natacion Tenerife Master. Estoy que no estoy a lo que estoy 🤷🏼‍♀️

[Cristina Tejera @cristinatejerap]

🔴 SYNCHRONIZE-MASLD @NatureMedicine

Survodutida 6,0 mg semanal en obesidad + MASLD de riesgo (fase 3, 48 sem):

📉 ≥30% reducción de grasa hepática (MRI-PDFF): 84,2% vs 24,3% placebo
🫀 −12,2% de peso vs −1,0%
🔬 61% normalizó la grasa hepática (<5%)

Mejoras además en cT1, ALT, AST, rigidez por VCTE y perfil cardiometabólico. Sin DILI, pancreatitis ni cáncer adjudicados.

Doble agonismo GCGR/GLP-1: efecto hepático más allá de la pérdida de peso.

🔗 https://t.co/pmJiAkTArh
#ADA2026 #ADAScisessions

[Cristina Tejera @cristinatejerap]

COMPETE SWITCH study

People with type 2 diabetes who were increased to semaglutide
2 mg were as likely to achieve an HbA1c less than 7% and more
likely to achieve greater than 5% weight loss than those who were switched to tirzepatide 2.5/5 mg , in real-world data #ada2026 #adascisessions

https://t.co/DdxdXi6NZy

[Michael Weintraub, MD @MWeintraubMD]

Retatrutide in adults with obesity over 104 weeks in the highest dose group had 30.3% weight loss.

Nearly 2/3 reached BMI &lt; 30

1 in 3 reached BMI &lt; 25

[Jen Can NuSH @JCanNuSH]

🚨TRANSCEND-T2D-1 full paper is out in Lancet. Retatrutide in T2D with diet and exercise. 40 weeks. Presenting at ADA 2926.
▪️Treatment regimen estimand: 1.94% reduction in A1C, 15.3% WL (Starting A1C of 7.9-8% average)
▪️Importantly, it doesn’t appear any of the arms had fully plateaued yet, but 4mg may have been getting there.
▪️53-59% females in retatrutide treatment arms, starting BMIs around 35-36
▪️Treatment discontinuations due to adverse events: 5%
▪️Nausea 26%, vomiting 18% (placebo had 4% and 2% respectively)

[Michael Weintraub, MD @MWeintraubMD]

We could prevent 55% of complex disease if we can treat underlying obesity.

What an unmet need and tremendous potential.

Dr. Sattar #ADASciSessions

[Marcos Gamboa @mrcsgmb84]

Nuevo análisis preespecificado del ensayo FIND-CKD: El rol de la Finerenona en la Enfermedad Renal Crónica por Glomerulopatías. 🧬.
🧵👇🏻
doi: 10.1001/jama.2026.9923
@SENefrologia @SLANH_ @SLANHJoven @GlomConILA @JonathanNefro @PepaSolerR @jorgericof @PerlaZambrano

[Judith López @Judithendo]

@albertlecube Crack!👏🏻👏🏻

[Albert Lecube @albertlecube]

Dicen que en la #ADA2026 los póster se cuelgan todos apaisados 😢... pero en vertical no quedan tan mal, ¿verdad?. Llaman más la atención 😅.

[Scott Isaacs @scottisaacsmd]

Systematic review and meta-analysis of weight loss with GLP-1 agonists.
https://t.co/dzBIilWYd8

[Daniel J Drucker @DanielJDrucker]

Identification of the acute pancreas-independent actions of GIP vs. GLP-1 in humans-note the profound actions of GIP on HR and DBP https://t.co/KhM4GEifP3

[Judith López @Judithendo]

@fjavesc @ehmet @icongetd @ana_sanchez_bao @marubioendocr @CarolPerdomoZ Jajaja, yo del 29 hasta hoy 🤪, xsiaca 😌

[Judith López @Judithendo]

@mrcsgmb84 @DaniMartinENDO @dremarquezr @drfherediaz @SABOURETCardio @cristinatejerap @CristobMorales @cristina_gavina @chemachir @jorgericof @PepaSolerR @FormigaFrancesc Mas allá del adipocito y más allá del islote!!! 🙌Que se dice pronto !!! Que herramientas to beat 👊🏻👊🏻👊🏻OBESITY, DM2 &amp; MORE😝😝😝

[Marcos Gamboa @mrcsgmb84]

El fin de la era "pesocéntrica" en la obesidad. ⚕️
La revisión clínica de The Lancet Diabetes & Endocrinology (2026) consolida a los coagonistas de incretinas como terapias sistémicas modificadoras de la enfermedad, más allá del adipocito. 🧵👇
https://t.co/GR1XsnmCS6
@SociedadSeedo @Diabetes_SEMI @redGDPS @ObesitySeen @SACcardiometab1 @IcyfaSemi @endocatracha @PerlaZambrano @SENefrologia @SLANH_ @fjavesc @albertlecube

[Judith López @Judithendo]

@drbennisahmed @jcobaya69 EXCELENT SUMMARY 🙌

[Ahmed Bennis MD 🫀 @drbennisahmed]

🔬 5 major obesity medicine updates from #ECO2026 — here’s what you need to know 🧵
1/ SURMOUNT-MAINTAIN — Zepbound works, but only if you stay on it.
Full dose → maintained ALL weight loss
Dropped to 5mg → regained ~12 lbs
Switched to placebo → regained up to 43 lbs
67% of placebo patients needed rescue therapy 😳
2/ ATTAIN-MAINTAIN — Oral Foundayo (orforglipron) after Wegovy/Zepbound preserved most weight loss vs. placebo. Transition drugs are viable. 💊
3/ High-dose Wegovy 7.2mg — Early responders lost an average of 27.7% body weight by week 72. Early response = strong predictor of outcomes. 📈
4/ Wegovy PILL (oral semaglutide 25mg) — Early responders lost 21.6% body weight by week 64 vs. 2.7% placebo. An oral GLP-1 that actually works. 🙌
5/ Body composition data — ~84% of weight lost was fat mass. Visceral fat ↓ >30%. Muscle function was preserved. This is the data we needed. 💪
🎯 The big takeaway: Long-term treatment, dose flexibility, and new oral options are shaping the future of obesity care. Personalized = sustainable = best results.
#ObesityMedicine #GLP1 #Tirzepatide #Semaglutide #ECO2026 #MedTwitter

[Judith López @Judithendo]

@RTVCes IMPRESENTABLE!Este paso atrás!!Anda keno hay cosas que implementar y modifican los que funcionan😤!! Influencias desde alguna perspectiva que se no escapa a los Endocrinólogos( especialistas que asisten a las personas con DM mas evolucionaras / mas complejas. UN PASO ATRÁS 😩😤!!

[La Vecina Rubia @lavecinarubia]

Hasta que Miguel Bosé no dé su opinión sobre el hantavirus estamos hablando sin saber.

[Judith López @Judithendo]

@drfherediaz @JonathanNefro Y GLP1 will be the next one!!
Mas Pilates que la mezquita de cordoba 💃💃👏🏻👏🏻👏🏻

[Jonathan Chávez @JonathanNefro]

Con enfermedad renal crónica tratada con iSGLT2, añadir finerenona, comparado a no hacerlo; se asoció a ↓74% el riesgo de perder &gt;30% de TFGe, mayor beneficio en aquellos que venían con deterioro más rápido. Seguimiento de 18 meses

Diabetes Obes Metab 2026
10.1111/dom.70821